FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3133670953> ?p ?o ?g. }

• W3133670953 endingPage "e249" @default.
• W3133670953 startingPage "e248" @default.
• W3133670953 abstract "We thank Juan Salvatierra and colleagues for their interest in our Article.1Cavalli G Larcher A Tomelleri A et al.Interleukin-1 and interleukin-6 inhibition compared with standard management in patients with COVID-19 and hyperinflammation: a cohort study.Lancet Rheumatol. 2021; (published online Feb 3.)https://doi.org/10.1016/S2665-9913(21)00012-6Summary Full Text Full Text PDF PubMed Scopus (128) Google Scholar Salvatierra and colleagues pose a critical question: how to select the right treatment and regimen for a patient with severe COVID-19. We posit that cytokine inhibition has a clear rationale in patients with severe COVID-19 with hyperinflammation, a condition caused by excess cytokine production and burdened by considerable mortality.2Cavalli G Dagna L The right place for IL-1 inhibition in COVID-19.Lancet Respir Med. 2021; (published online Jan 22.)https://doi.org/10.1016/S2213-2600(21)00035-7Summary Full Text Full Text PDF PubMed Scopus (30) Google Scholar In patients with severe COVID-19 and hyperinflammation, inhibiting excess cytokine production might reduce mortality. Hence, throughout our studies, we did not treat patients with mild or moderate disease or those without evidence of hyperinflammation, as we feel that many of these individuals have an appropriate immune response to the virus.1Cavalli G Larcher A Tomelleri A et al.Interleukin-1 and interleukin-6 inhibition compared with standard management in patients with COVID-19 and hyperinflammation: a cohort study.Lancet Rheumatol. 2021; (published online Feb 3.)https://doi.org/10.1016/S2665-9913(21)00012-6Summary Full Text Full Text PDF PubMed Scopus (128) Google Scholar, 3Cavalli G De Luca G Campochiaro C et al.Interleukin-1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinflammation: a retrospective cohort study.Lancet Rheumatol. 2020; 2: e325-e331Summary Full Text Full Text PDF PubMed Scopus (743) Google Scholar Conversely, we selectively and consistently evaluated anakinra in patients with severe COVID-19, respiratory insufficiency, and hyper-inflammation (defined as serum C-reactive protein ≥100 mg/L, ferritin ≥900 ng/mL, or both). In this population of patients with severe COVID-19, we initially evaluated low-dose subcutaneous anakinra (100 mg twice daily). However, we found that treatment with low-dose subcutaneously was neither associated with reductions in serum C-reactive protein nor with meaningful improvements in clinical status at day 7.3Cavalli G De Luca G Campochiaro C et al.Interleukin-1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinflammation: a retrospective cohort study.Lancet Rheumatol. 2020; 2: e325-e331Summary Full Text Full Text PDF PubMed Scopus (743) Google Scholar Although no safety concerns emerged, the lack of marked clinical or anti-inflammatory effects led to early termination of this preliminary experience and prompted the evaluation of higher doses (5 mg/kg twice a day) and intravenous administration, which we found to be efficacious. Of note, anakinra had been previously used intravenously and at doses that far exceed those approved for licensed indications: for example, high-dose intravenous anakinra was evaluated in previous studies of septic shock and macrophage activation syndrome, both conditions sharing similarities with severe COVID-19.1Cavalli G Larcher A Tomelleri A et al.Interleukin-1 and interleukin-6 inhibition compared with standard management in patients with COVID-19 and hyperinflammation: a cohort study.Lancet Rheumatol. 2021; (published online Feb 3.)https://doi.org/10.1016/S2665-9913(21)00012-6Summary Full Text Full Text PDF PubMed Scopus (128) Google Scholar, 3Cavalli G De Luca G Campochiaro C et al.Interleukin-1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinflammation: a retrospective cohort study.Lancet Rheumatol. 2020; 2: e325-e331Summary Full Text Full Text PDF PubMed Scopus (743) Google Scholar Overall, anakinra has a remarkable record of safety, as a short half-life allows prompt discontinuation in the event of adverse events including bacterial infections. It is probable that in early phases of COVID-19, viral-induced necrotic cell death of pneumocytes results in the release of IL-1α, which fosters local inflammation; eventually, this and other mediators induce the release of IL-1β by infiltrating myeloid cells, which results in runaway inflammatory responses.4Cavalli G Farina N Campochiaro C et al.Repurposing of biologic and targeted synthetic anti-rheumatic drugs in COVID-19 and hyper-inflammation: a comprehensive review of available and emerging evidence at the peak of the pandemic.Front Pharmacol. 2020; 11598308Crossref PubMed Scopus (26) Google Scholar Thereby, it is certainly possible that lower doses of anakinra might be effective when used in earlier stages of disease development, or in patients with less severe disease, as suggested by Salvatierra and colleagues. Indeed, Huet and colleagues (among others) found lower disease regimens to be also effective in COVID-19.5Huet T Beaussier H Voisin O et al.Anakinra for severe forms of COVID-19: a cohort study.Lancet Rheumatol. 2020; 2: e393-e400Summary Full Text Full Text PDF PubMed Scopus (459) Google Scholar However, information on the best treatment regimen cannot be extrapolated from indirect comparisons between different studies. Nor should concerns about potential toxicity discourage us from titrating anakinra to the dosage that is clinically needed for optimal suppression of IL-1-mediate inflammation, since undertreating severe COVID-19 is likely to pose more threats than overdosing anakinra. GC and LD declare consultation honoraria from Sobi, Roche, and Sanofi outside the submitted work. AL and AT declare no competing interests. Interleukin-1 and interleukin-6 inhibition in patients with COVID-19 and hyperinflammationWe read with interest the study by Giulio Cavalli and colleagues.1 The Article compares the clinical effectiveness of IL-1 inhibition (anakinra) and IL-6 inhibition (tocilizumab or sarilumab) with standard treatment in a large homogeneous cohort of patients with COVID-19, respiratory insufficiency, and hyperinflammation. Full-Text PDF Interleukin-1 and interleukin-6 inhibition compared with standard management in patients with COVID-19 and hyperinflammation: a cohort studyIL-1 inhibition, but not IL-6 inhibition, was associated with a significant reduction of mortality in patients admitted to hospital with COVID-19, respiratory insufficiency, and hyperinflammation. IL-6 inhibition was effective in a subgroup of patients with markedly high C-reactive protein concentrations, whereas both IL-1 and IL-6 inhibition were effective in patients with low lactate dehydrogenase concentrations. Full-Text PDF" @default.
• W3133670953 created "2021-03-15" @default.
• W3133670953 creator A5022182189 @default.
• W3133670953 creator A5027512145 @default.
• W3133670953 creator A5030743413 @default.
• W3133670953 creator A5033287794 @default.
• W3133670953 date "2021-04-01" @default.
• W3133670953 modified "2023-10-10" @default.
• W3133670953 title "Interleukin-1 and interleukin-6 inhibition in patients with COVID-19 and hyperinflammation – Authors' reply" @default.
• W3133670953 cites W3023088605 @default.
• W3133670953 cites W3030325615 @default.
• W3133670953 cites W3110786572 @default.
• W3133670953 cites W3124672192 @default.
• W3133670953 doi "https://doi.org/10.1016/s2665-9913(21)00066-7" @default.
• W3133670953 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7990474" @default.
• W3133670953 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33782670" @default.
• W3133670953 hasPublicationYear "2021" @default.
• W3133670953 type Work @default.
• W3133670953 sameAs 3133670953 @default.
• W3133670953 citedByCount "4" @default.
• W3133670953 countsByYear W31336709532021 @default.
• W3133670953 countsByYear W31336709532022 @default.
• W3133670953 countsByYear W31336709532023 @default.
• W3133670953 crossrefType "journal-article" @default.
• W3133670953 hasAuthorship W3133670953A5022182189 @default.
• W3133670953 hasAuthorship W3133670953A5027512145 @default.
• W3133670953 hasAuthorship W3133670953A5030743413 @default.
• W3133670953 hasAuthorship W3133670953A5033287794 @default.
• W3133670953 hasBestOaLocation W31336709531 @default.
• W3133670953 hasConcept C11988809 @default.
• W3133670953 hasConcept C126322002 @default.
• W3133670953 hasConcept C203014093 @default.
• W3133670953 hasConcept C2778690821 @default.
• W3133670953 hasConcept C2779134260 @default.
• W3133670953 hasConcept C3008058167 @default.
• W3133670953 hasConcept C524204448 @default.
• W3133670953 hasConcept C71924100 @default.
• W3133670953 hasConcept C72563966 @default.
• W3133670953 hasConcept C74172505 @default.
• W3133670953 hasConcept C90924648 @default.
• W3133670953 hasConceptScore W3133670953C11988809 @default.
• W3133670953 hasConceptScore W3133670953C126322002 @default.
• W3133670953 hasConceptScore W3133670953C203014093 @default.
• W3133670953 hasConceptScore W3133670953C2778690821 @default.
• W3133670953 hasConceptScore W3133670953C2779134260 @default.
• W3133670953 hasConceptScore W3133670953C3008058167 @default.
• W3133670953 hasConceptScore W3133670953C524204448 @default.
• W3133670953 hasConceptScore W3133670953C71924100 @default.
• W3133670953 hasConceptScore W3133670953C72563966 @default.
• W3133670953 hasConceptScore W3133670953C74172505 @default.
• W3133670953 hasConceptScore W3133670953C90924648 @default.
• W3133670953 hasIssue "4" @default.
• W3133670953 hasLocation W31336709531 @default.
• W3133670953 hasLocation W31336709532 @default.
• W3133670953 hasOpenAccess W3133670953 @default.
• W3133670953 hasPrimaryLocation W31336709531 @default.
• W3133670953 hasRelatedWork W1646653418 @default.
• W3133670953 hasRelatedWork W1971944195 @default.
• W3133670953 hasRelatedWork W2029595088 @default.
• W3133670953 hasRelatedWork W2066137140 @default.
• W3133670953 hasRelatedWork W2085673832 @default.
• W3133670953 hasRelatedWork W2085829142 @default.
• W3133670953 hasRelatedWork W2090594461 @default.
• W3133670953 hasRelatedWork W2133618989 @default.
• W3133670953 hasRelatedWork W2414766522 @default.
• W3133670953 hasRelatedWork W2912786107 @default.
• W3133670953 hasVolume "3" @default.
• W3133670953 isParatext "false" @default.
• W3133670953 isRetracted "false" @default.
• W3133670953 magId "3133670953" @default.
• W3133670953 workType "article" @default.